P rimary percutaneous coronary intervention (pPCI) has significantly reduced cardiovascular mortality of patients with ST-segment-elevation myocardial infarction (STEMI).
PROSPECT CMR Study
However, even rapid and complete restoration of culprit vessel flow may not guarantee adequate myocardial perfusion and may be associated with poor recovery of left ventricular (LV) function and unfavorable remodeling, which are major predictors of morbidity and mortality. 3 Prediction of future cardiovascular events after STEMI aroused much interest during the past few decades. 4 Typically, risk stratification is performed using electrocardiography, laboratory angiography and echocardiography parameters, and proven risk scores. 5, 6 Cardiac magnetic resonance (CMR) has emerged as the gold standard technique for the measurement of the LV ejection fraction (LVEF), the amount of saved myocardium as expressed by myocardial salvage index (MSI), microvascular obstruction (MVO), and myocardial hemorrhage (MH). 7, 8 These variables may predict LV functional recovery 9 and risk of major adverse cardiovascular events (MACE). 10, 11 Thus, we hypothesized that a multiparametric CMR score has incremental prognostic value as compared with standard prognostic stratification.
Methods

Study Population
Two hundred fifty-five consecutive patients with STEMI, referred to our hospital between January 2012 and December 2014, were prospectively screened to identify those meeting the following inclusion criteria: (1) chest pain suggestive of myocardial ischemia lasting >30 minutes, (2) ST-segment elevation >0.1 mV in ≥2 limb leads or >0.2 mV in ≥2 contiguous precordial leads, or presumed new left bundlebranch block, and (3) successful treatment with pPCI within 12 hours from symptom onset. Exclusion criteria were prior myocardial infarction (MI) or revascularization, time to pPCI >12 hours, atrial fibrillation, Killip class >III, renal failure (glomerular filtration <30 mL/ min), claustrophobia or other contraindications to CMR, and insufficient T2w-image quality. The study complied with the declaration of Helsinki; the ethics committee approved the research protocol, and each patient gave informed consent (protocol number, R49416).
Collection of Clinical Variables
Clinical history and the following variables were collected in each patient: demographic characteristics, cardiovascular risk factors, medical therapy, vital parameters including blood pressure and heart rate, MI location, peak CK-MB and troponin I, Killip class, and time to pPCI defined as the interval time between onset of continuous chest pain and recanalization of the infarct-related artery by pPCI. Finally, global registry of acute coronary events (GRACE) 2.0 risk score was calculated for each patient. 12 
Invasive Coronary Angiography
All coronary angiograms were analyzed by an experienced interventional cardiologist (A.L.B, with >10 years of clinical experience in invasive coronary angiography performance and analysis). The following parameters were collected: medications before pPCI, infarct-related artery, Rentrop grade, 13 collateral circulation defined as Rentrop grade ≥2, and thrombolysis in MI flow grade before and after pPCI.
Transthoracic Echocardiography
Transthoracic echocardiography (TTE) was performed the third day after pPCI using a commercially available system (IE33 system; Philips Medical System, Andover, MA) in the parasternal (long-and short-axis) and apical (2-, 3-, and 4-chamber) views. Echocardiographic measurements were performed twice to evaluate the intraobserver variability by an expert reader (M.G. with >5 years of clinical experience in TTE performance and analysis, certified by the Italian Society of Echocardiography) blinded to patient clinical history. 14 In each patient, LV end-diastolic (LVEDV) and end-systolic (LVESV) volumes were measured on apical 4-chamber and 2-chamber views by Simpson method. In detail, volume measurements were based on tracings of the blood tissue interface in the apical 4-and 2-chamber views. At the mitral valve level, the contour was closed by connecting the 2 opposite sections of the mitral ring with a straight line. LV length was defined as the distance between the middle of this line and the most distant point of the LV contour. Accordingly, we measured LVEF with the following equation: (LVEDV−LVESV)/LVEDV. For LV-wall motion analysis by using the American Heart Association 17-segment model. 15 Tricuspid annular plane systolic excursion was derived by placing the M-mode cursor along the lateral tricuspid annulus measuring the distance of movement on an apical 4-chamber view. By means of a simplified Bernoulli equation, velocity of the tricuspid regurgitant jet was used to calculate pulmonary artery systolic pressure (PASP) according to the following equation: 4×(velocity of the tricuspid regurgitant jet) 2 +right atrial pressure. Another expert reader (M.P. with >10 years of clinical experience in TTE performance and analysis, certified by the Italian Society of Echocardiography) repeated TTE measurements to assess interobserver variability.
CMR Protocol and Analysis
All patients were studied with a 1.5-T scanner (Discovery MR450; GE Healthcare, Milwaukee, WI) using dedicated cardiac software, phased-array surface receiver coils, and ECG triggering the third day after pPCI. Data were transferred to a dedicated postprocessing workstation (Report Card 4.0; GE Healthcare) and evaluated twice by a reader with 5 years of experience in CMR (G.P. with level III European Society of Cardiology certification). The operator was blinded to patients' clinical history and TTE results. Another reader with 5 years of experience in CMR (S.M. with level III ESC certification) repeated the CMR data analysis for intraobserver and interobserver variability assessment.
Briefly, after acquisition of localizer images breath-hold steadystate free-precession cine CMR was performed in cardiac vertical and horizontal long-axis and short-axis orientations (echo time, 1.57 ms; 15 segments; repetition time, 46 ms without view sharing; slice thickness, 8 mm; field-of-view, 350×263 mm; and pixel size, 1.4×2.2 mm).
The following parameters were measured: LVEDV and LVESV, LVEF, LV mass, right ventricular end-diastolic volume, right ventricular end-systolic volume, and right ventricular ejection fraction. Breath-hold black-blood T2-weighted short inversion time inversionrecovery fast spin-echo (T2w) was performed with the same prescription of cine CMR images. T2w-image quality was assessed using a 4-grade score: (1) poor, (2) moderate, (3) good, and (4) excellent. Exams with a score 1 were excluded. In the LV myocardial wall supplied by the infarct-related artery, myocardial tissue with a signal intensity (SI) 2 SD above the mean SI of the noninfarcted myocardium was considered area at risk (AAR). The contours of automatically detected AAR were manually adapted to exclude increased SI from the adjacent blood pool (slow flow) or artifacts because of cardiac motion or respiration. MH was defined as a ≥1 mL hypointense area of myocardium with a mean SI below 2 SD of that of the periphery of the AAR. MH was considered part of myocardial edema for calculating AAR. Ten minutes after a contrast bolus of 0.1 mmol/ kg of gadolinium-BOPTA (Multihance; Bracco, Milan, Italy), breathhold contrast-enhanced segmented T1-weighted inversion-recovery gradient-echo images were acquired with the same prescriptions for cine images to detect late gadolinium enhancement (LGE). The inversion time was individually adjusted to null normal myocardium. On postcontrast imaging, LGE was considered present if SI of the hyperenhanced myocardium was >5 SD above the mean SI of remote myocardium 16 and was measured as absolute mass or as percentage of entire LV mass. Postcontrast images were used to detect MVO defined as a hypoenhanced region within the infarcted myocardium. When present, MVO was included in the hyperintense myocardium for LGE quantification. Finally, the MSI was calculated according to the following equation (AAR-LGE)/AAR and expressed as absolute number ranging between 0 and 1. PROSPECT CMR Study
Follow-Up and End Points
Trained physicians performed follow-up with office visits and phone contact. If a patient missed the follow-up visit, telephone contact, review of outpatient clinic or hospital records was performed and patient's primary care physician or cardiologist were contacted. The follow-up interviewer was blinded to baseline, TTE, and CMR data. An independent clinical events committee (G.P., A.I.G., and M.P.) adjudicated all MACE events in a blinded fashion using standard, prospectively determined definitions (Data Supplement). The following end points were evaluated in case of simultaneous or multiple events (for the definition of each end point, see the Data Supplement): (1) unplanned revascularization, (2) planned revascularization, (3) nonfatal MI, (4) periprocedural MI, (5) implantable cardioverter defibrillator implantation, (6) congestive heart failure, and (7) cardiovascular death or aborted cardiovascular death.
The primary end point was defined as any MACE including congestive heart failure or cardiac death or aborted cardiac death. In patients experiencing simultaneous or multiple events, the one that met the definition of MACE was counted.
Statistical Analysis
Statistical analysis was performed with SPSS, version 23, software (SPSS, Inc, Chicago, IL) and R version 2.15.2. Continuous variables were expressed as mean±SD or median (25th-75th percentile) as appropriate and discrete variables as absolute numbers and percentages. Intraobserver and interobserver variability for evaluation of TTE and CMR variables were performed by intraclass correlation coefficients for continuous variables and κ test for categorical variables. Student-independent t or Mann-Whitney U tests were used as appropriate to compare continuous variables between patients with and without MACE. Comparisons between groups of discrete variables were performed by χ 2 or Fisher exact test if the expected cell count was <5. Univariable Cox proportional hazard models were used to assess the association between baseline covariates expressed as continuous and dichotomous variables and the composite end point (results presented as hazard ratio and 95% confidence interval). To identify the optimal threshold for MACE diagnosis, the Youden index was computed for TTE and CMR parameters showing the lowest P value at univariate analysis. Then, a stepwise selection procedure was applied (P<0.05 for entry) for CMR parameters, and based on the result of the multivariate model, the additive value of each variable was evaluated on the basis of the increase of χ 2 of the model to create a CMR score. Finally, the incremental value in predicting the composite end point by inclusion of TTE-LVEF and CMR score in addition to GRACE score was assessed by the χ 2 using Omnibus test of model coefficients and by the comparison of area under the receiver operating characteristic curve (C statistic). Reclassification of patients was determined using net reclassification improvement analysis for MACE and obtained by adding TTE-LVEF and CMR score to the model based on GRACE score. All tests were 2 tailed, and a P value <0.05 was considered statistically significant. Figure 1 shows the workflow of our study population. Thirtyfive patients who met exclusion criteria were excluded. Further, 6 patients with poor image quality of T2w images were excluded. Of note, these 6 patients were similar in terms of baseline characteristics as compared with the overall population (5 men; mean age, 61.6±11 years; body mass index, 26.7±3.5; TTE-LVEF, 52±9.8%; CMR-LVEF, 50±10.2%), and no MACE were observed during the follow-up. Therefore, the final study population included 209 patients. Table 1 . Eighty-three (40%) patients had an anterior STEMI with a mean GRACE risk score of 10.6±6.5%.
Results
TTE and CMR Findings
The mean LVEF at TTE and CMR was 51.5±10% and 49±10% (Table 2 ), respectively. CMR showed an AAR and LGE involving 26±20% and 17±15% of LV mass, respectively (Table 2) . MVO and MH occurred in 70 (34%) and 34 (16%) patients (Table 2) , respectively. Intraobserver and interobserver intraclass correlation for TTE-LVEF evaluation was 0.81 and 0.78, respectively. CMR intraobserver and interobserver intraclass correlation for LVEF, MSI, MVO, and MH detection were 0.88, 0.92, 0.89, 0.82 and 0.84, 0.86, 0.82, 0.75, respectively.
Major Adverse Cardiac Events
All patients were followed-up for an average of 2.5±1.2 years. No patient was lost to follow-up. Revascularization, nonfatal MI, implantable cardioverter defibrillator implantation, congestive heart failure, and cardiac death occurred in 44 (21%), 10 (5%), 10 (5%), 21 (10%), and 3 (1%) patients, respectively. In 34 patients with bystander disease, a further elective revascularization was performed within 45 days after the index angiogram according to local practice. No periprocedural MI occurred in this subset of patients. Further, 10 unplanned revascularizations were performed during the follow-up (4 patients for unstable angina and 6 patients for recurrent chest pain with a positive functional stress test). Among 10 patients with nonfatal MI, 2 were because of early stent thrombosis and 8 were secondary to progression or denovo coronary artery disease. Among 10 patients who experienced implantable cardioverter defibrillator implantation, no additional events were observed. Among 21 patients who experienced heart failure, 2 were implanted with implantable cardioverter defibrillator during follow-up. Finally, among the 3 patients who died, no events were observed before death. MACE occurred in 24 (11%) patients. Of note, no differences were found in terms of reinfarction distribution between the no-MACE and MACE groups (8 versus 2, P=0.38).
TTE and CMR Findings in Patients Without MACE Versus Patients With MACE
At follow-up, patients with MACE showed higher LVEDV, LVESV, and lower LVEF (P<0.01) with both imaging modalities as compared with those without MACE ( Table 2) . Additionally, patients with MACE showed similar AAR but higher LGE, MVO, and MH prevalence with lower MSI as compared with patients without MACE (P<0.001; Table 2 ). Of note, among patients with TTE-LVEF ≥55%, the prevalence of MACE was low compared with patients with TTE-LVEF <55% (3% versus 17%; P<0.01).
MACE and Survival Predictors
On univariable analysis, GRACE score, TTE-LVEF, CMR-LVEF, LGE, MVO, MH, and MVO were all predictors of MACE (Table 3) . At Youden test analysis, among the TTE and CMR parameters, the best cut-off values of TTE-LVEF, (Table 5 ). The 3 predictive models showed a C statistic of 0.63, 0.74, and 0.87, respectively. Figure 2 shows the comparison between the net reclassification improvement of each predictive model. Figure 3 shows the different CMR phenotypes and their relationship with outcome.
Discussion
In this single-center study, we found that an integrated model, including CMR findings, provided additional prognostic value as compared with clinical risk scores and TTE-derived LVEF.
Previous studies demonstrated that the estimation of LVEF is limited to stratify patients who experienced MACE. To this regard, in a series of 2130 patients with MI, Makikallio et al 17 found that 67% of cardiac deaths occurred in individuals with LVEF >35%. On the contrary, Huikuri et al, 18 showed that ventricular tachycardia occurred only in 8% of 312 patients with STEMI with reduced LVEF at 2-year follow-up. Therefore, further risk stratification of patients based on superior LVEF quantification and direct visualization of tissue damage is desirable. To this regard, several studies evaluated the prognostic value of CMR in post-STEMI patients. CMR imaging is a standardized technique with high spatial resolution that is independent of geometric assumptions and represents the standard modality for LV volume and LVEF measurements. Indeed, a significant discrepancy between CMR and TTE has been demonstrated, with the majority of studies indicating an overestimation of LVEF assessment by TTE. 10 Wu et al 19 demonstrated that both infarct size and MVO predict long-term prognosis in 44 consecutive patients with acute infarction. However, beyond the small sample size of this preliminary experience, the technical limitation of the sequences used at that time allowed only 4 base-to-apex shortaxis cross sections and required long and multiple breath holds. As a consequence, the role of MVO was evaluated as a dichotomous variable, and the rate of unevaluable cases was high. In a larger series, Hombach et al 20 showed that MVO predicts adverse remodeling, but also in this case, MVO was evaluated as a binary variable. Moreover, in both studies, the More recently, in a study of 278 patients with STEMI, De Waha et al 21 demonstrated that a CMR model including LVEF, infarct size, MVO, and MSI added incremental prognostic value above traditional outcome markers alone. Eitel et al 4 enrolled 738 patients with STEMI from 8 centers and showed that infarct size and MVO provided incremental prognostic value above clinical risk assessment plus LVEF evaluation with a c-index increase from 0.761 to 0.801 (P=0.036). However, despite the latter studies having used more recent CMR technology, they were limited by the lack of information on the additional value of CMR findings compared with standard clinical scores and TTE.
Similar to MVO, MH is an index of microvascular pathology that may have clinical value. Carrick et al, 8 using T2 mapping instead of T2-weighted images, detected MH in 41% of 286 consecutive patients with STEMI and demonstrated that this index was more closely associated with adverse outcomes than MVO.
Our study has several strengths compared with previous articles. First, few reports have tested the additional prognostic value of microvascular function indices detectable by CMR compared with the integrated use of GRACE score and TTE-assessed LVEF. Second, different from other studies, in our prognostic model we included CMR parameters, such as MVO, as a continuous rather than dichotomous variable. Third, to consider prespecified adverse health outcomes that are pathophysiologically linked with STEMI, MACE included congestive heart failure and cardiac death. This may explain the low number of MACE events but further reinforces the prognostic value of CMR indices in the prediction of hard clinical events. Fourth, a committee adjudicated all end points. Finally, the ratio between anterior and inferior STEMI was more balanced compared with previous studies in which anterior STEMI were the majority. 
Study Limitations
Several limitations of our study should be acknowledged. First, the small sample size and the single-center nature of the study limit the robustness of results. For this reason, to split the study population in a derivation and validation cohort is not feasible. Second, MACE rate was low and, therefore, our predictive model may have experienced overfitting. Third, AAR and MH were detected by dark blood T2-weighted images that may have been hampered by imaging artifacts. On the contrary, both T1 and T2 mapping may overcome this limitation. 26 Verhaert et al 27 showed that recent ischemic Figure 2 . Incremental value of cardiac magnetic resonance (CMR) score in predicting major adverse cardiac events when compared with models including global registry of acute coronary events (GRACE) score in combination with transthoracic echocardiography (TTE)-left ventricular ejection fraction (LVEF). IDI indicates integrated discrimination improvement; and NRI, net reclassification improvement. PROSPECT CMR Study injury was quantitatively differentiated from remote myocardium by its higher T2 value in 96% of patients enrolled in the study compared with 67% by black-blood T2-weighted imaging, highlighting the superiority of quantitative T2 mapping. Several reasons can explain the limited robustness of black-blood T2-weighted imaging, such as surface coil intensity inhomogeneity leading to variability in myocardial signal, subendocardial bright signal artifact caused by stagnant blood, cardiac motion leading to reduced myocardial signal, and the subjective nature of qualitative T2-weighted image analysis. 28 However, black-blood T2-weighted imaging is the most widely used technique in clinical practice and, therefore, more clinically applicable compared with a model including T2 mapping.
Of note, we only included patients with CMR exams showing adequate T2-weighted images. Fourth, breath-hold contrast-enhanced segmented T1-weighted inversion-recovery gradient-echo images were used to detect scar rather than phase-sensitive inversion-recovery sequences. Fifth, we excluded high-risk patients, including patients with advanced Killip class at presentation who may have low compliance to CMR. Indeed, it is difficult to avoid CMR dropout of STEMI patients, a limitation currently shared by all CMR studies in this clinical setting. However, Larsen et al 29 found that higher baseline risk in the dropout group did not affect clinical outcomes.
Sixth, we did not include promising prognostic markers, such as brain natriuretic peptide and soluble ST2, in our model. Indeed several studies 30, 31 have shown that both markers were independently associated with adverse prognosis beyond other biomarkers, such as cardiac troponin. Whether CMR findings provide additional prognostic information compared with these novel biomarkers is still unknown, and further studies in this area are warranted.
Finally, whether all patients who experience STEMI or a subgroup of STEMI individuals should undergo CMR cannot be evaluated in this study because of the small sample size and low number of MACE.
Conclusions
We found that a CMR score based on LVEF estimation, MSI, and presence and amount of MVO and MH provides incremental prognostic value compared with standard prognostic stratification, including GRACE score and TTE-LVEF. Future , and no evidence of myocardial hemorrhage (MH) and microvascular obstruction (MVO) who did not experience major adverse cardiac events (MACE); phenotype 2: patient with moderate LV dysfunction with both imaging modalities, low MSI, and evidence of both MH and MVO who died; phenotype 3: patient with moderate LV dysfunction with transthoracic echocardiography (TTE) who was reclassified as having severe LV ejection fraction (LVEF) reduction by CMR. Moreover, low MSI and presence of both MH and MVO were detected by CMR. The patient experienced HF and aborted cardiac death. HF indicates heart failure; IR, inversion recovery; and LGE, late gadolinium enhancement. PROSPECT CMR Study prospective multicenter studies with larger sample sizes are warranted because CMR parameters may impact the management of patients with STEMI.
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